Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Zoster Treatment Market size is poised to witness over 13.8% CAGR during the forecast period i.e., between 2025-2037.
The growth of the market can be primarily attributed to the high prevalence of the sickness and its increasing commonness among older populations. According to the Centers for Disease Control and Prevention, every year, a total of one million cases of herpes zoster occurs in the United States alone. The incidence of the disease among elderly population of 60 years and above is 1 case per 100 in the country.
In addition to these, the rising introduction of vaccines and medications for self-treatment, with the aim to opt for hospitalization only when of utmost necessity, is also a crucial factor expected to drive market growth in the upcoming years. Furthermore, upsurge in investments by prominent market players to develop effective and improved treatment for cutaneous viral infections is projected to offer profitable opportunities to the zoster treatment market in the near future.
Zoster Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- High Prevalence of Zoster Globally
- Rising Introduction of Vaccines and Medications for Self-Treatment
Challenges
- High Cost of Treatment of Zoster
Zoster Treatment Segmentation
The market is segmented by treatment type into antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, creams, and Zostavax, out of which, the antiviral medications segment is anticipated to hold the largest share in the global zoster treatment market. This can be accounted to the ability of these medications to shorten the length of a viral infection, and their effectiveness in shortening the course of several viral illnesses. Additionally, on the basis of route of administration, the oral segment is predicted to acquire the largest share during the forecast period. Acyclovir, famciclovir and valacyclovir are some of the most common drugs for treating zoster, which are taken via oral route of administration. This in turn is largely forecasted to drive the growth of the market segment in the future.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
End User |
|
|
Route of Administration |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportZoster Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the zoster treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific industry is estimated to account for largest revenue share by 2037, propelled by growing occurrence of herpes zoster, and rising initiatives by governmental and non-governmental organizations associated with vaccination drives. Moreover, the market in North America is anticipated to acquire the largest share over the forecast period owing to the public authority support in several vaccination and awareness projects, and increasing elderly population in the region. Apart from these, allocation of high healthcare expenditure is also expected to boost the region’s zoster treatment market growth in the imminent time. As per the Centers for Medicare and Medicaid Services, the healthcare spending in the United States reached a value of USD 3.8 trillion, or USD 11,582 per person in 2019. The health spending accounted for 17.7 percent of the nation’s GDP.
Companies Dominating the Zoster Treatment Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Valeant Pharmaceuticals North America, LLC
- Merck & Co., Inc.
- Abbott Laboratories
- Teva Pharmaceutical Ltd
- Camber Pharmaceuticals, Inc.
- Gilead Sciences Inc.
- Mylan NV
- GlaxoSmithKline plc
- Maruho Co. Ltd.
In the News
-
July 2021- GlaxoSmithKline announced that the U.S. Food and Drugs Administration approved Shingrix for the prevention of herpes zoster in adults aged 18 years or older, who are at increased risk of the condition
Author Credits: Radhika Pawar
- Report ID: 3620
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
